Cord Blood Banking Market to Hit $50B

The first successful cord blood transplant occurred in 1988, treating a five-year-old boy with Fanconi Anemia using stem cells from his newborn sister's umbilical cord. This groundbreaking procedure demonstrated the viability of cord blood as a source of hematopoietic stem cells, which can regenerate the blood and immune systems. Following this success, the first public cord blood bank was established in New York in 1992, allowing for unrelated donor transplants. The first private bank also opened that year, offering families the option to store their baby's cord blood for their own potential future use, a service often likened to "biological insurance." Today, cord blood stem cells are FDA-approved for treating more than 80 diseases, including various cancers like leukemia and lymphoma, as well as blood disorders such as sickle cell anemia and thalassemia. Transplants using related cord blood have shown success rates twice as high as those using blood from an unrelated donor. The industry is divided into two main models: private and public banks. Private banks charge fees for collection and annual storage for a family's exclusive use. Public banks accept donations free of charge, making the stem cells available to any matching patient in need, though this means the original family may not have access to it later. A major historical limitation has been the small number of stem cells in a single cord blood unit, often insufficient for treating adult patients. However, in April 2023, the FDA approved Omisirge, the first "expanded" cord blood therapy, which multiplies the number of stem cells, significantly broadening treatment possibilities. Beyond established treatments, research is exploring cord blood's role in regenerative medicine. Clinical trials are underway for conditions like cerebral palsy, autism, and brain injuries, with some studies showing improved motor skills in children with cerebral palsy who received infusions of their own cord blood.